Share this link via:
The global Huntington's disease market size was valued at USD 642.7 million in 2025 and is projected to reach USD 868.2 million in 2026, expanding to USD 2,623.4 million by 2034, growing at a CAGR of 17.1% during the forecast period (2026-2034).
Huntington’s disease can be defined as a progressive and hereditary neurodegenerative disorder marked by uncontrollable body movements and psychological and emotional issues, as well as cognitive deficits, which occur due to the increased number of CAG repeats in the huntingtin gene, causing the accumulation of the mutated huntingtin protein in the brain and causing selective damage to the striatal neurons and the cortex. The symptoms of the condition develop over a span of 15-20 years after onset, requiring lifelong treatment of those affected and their extended families at risk of developing the condition.
Treatment of Huntington’s disease consists of advanced pharmaceutical options that include various symptom complexes such as involuntary choreiform movements that can be controlled using monoamine-depleting drugs and antipsychotics; psychiatric symptoms, including depression, anxiety, and apathy, that can be controlled using selective serotonin reuptake inhibitors and a new generation of psychotropic drugs; cognitive impairments that need neuroprotective measures and new disease-modifying drugs for prevention of huntingtin protein deposition; and motor deficits that can be controlled with physical therapy and symptomatic drugs. The treatment of the disease has undergone revolutionary change from being solely symptom-based to emerging disease-modifying treatments with the use of gene therapy, RNA interference, and protein-based treatments that focus on the underlying pathogenesis rather than the symptoms.
Clinical relevance goes beyond the treatment of individual patients but rather encompasses the management of a disease through an ecosystem consisting of genetic diagnosis by means of predictive testing, pre-symptom genetic counseling, disease management through biomarkers such as neuroimaging and cerebrospinal fluid markers, participation in clinical trials for disease-modifying drugs, and caregiver support programs for the significant psychosocial burden associated with the disease. The total number of individuals suffering from Huntington's disease globally is about 44,000 in 2025, while there are about 200,000 people with Huntington's gene mutation in their families and need genetic counseling, early detection, and prevention strategies. This presents a significant market for chronic disease management with various applications of therapies beyond drug treatments.
|
Market Metric |
Details & Data (2026-2034) |
|
2025 Market Valuation (Base Year) |
USD 642.7 Million |
|
2026 Estimated Value |
USD 868.2 Million |
|
2034 Projected Value |
USD 2,623.4 million |
|
CAGR (2026-2034) |
17.1% |
|
Market Scope |
2022-2034 |
|
Report Coverage |
Revenue Forecast, Treatment Assessment, Clinical Trial Pipeline Analysis, Biomarker Development, Genetic Testing Market, Regulatory Landscape |
|
Segments Covered |
By Treatment Type, Drug Class, Indication, Delivery Method, End-User |
|
Geographies Covered |
North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
|
Countries Covered |
US, Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, South Korea, Australia, Brazil, Argentina, South Africa, Saudi Arabia, UAE |
|
Dominant Region |
North America |
|
Fastest Growing Region |
Asia Pacific |
|
Key Market Players |
H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Novartis AG, uniQure NV, Roche/Genentech, Regeneron Pharmaceuticals |
Huntington’s disease market growth globally is being driven by heightened awareness about the disease and improvements in diagnosis and treatment, as well as increases in the population that carries a genetic predisposition to the condition. Huntington’s disease is an inherited neurodegenerative disease characterized by autosomal dominant inheritance, which translates to a 50% probability of passing it on to the next generation. Improved provision of genetic testing and counseling services has been driving increased numbers of both symptomatic patients and asymptomatic mutation carriers.
Increased awareness among health care practitioners and families of patients has helped in reducing delays in diagnoses in advanced health care environments. Apart from diagnosed patients, a significantly larger population that is at risk needs regular genetic counseling, neurological evaluation, biomarker testing, and imaging. The growth in screening programs for early diagnosis and improvements in predictive diagnostics is increasing the demand for specialized clinical services and opening new opportunities in the disease-modifying drug development field.
The market for Huntington’s disease treatments is undergoing a fundamental change owing to the recent advances made in gene therapy and RNA interference-based therapeutic approaches that address the root cause of the disease. The AMT-130 therapy, which is an adeno-associated virus serotype 5 gene therapy drug, has already shown promising clinical benefits through reduced levels of mutant huntingtin protein, slowing of the progression of the disease, and safety attributes, hence justifying further accelerated development. Meanwhile, RNA interference therapeutic approaches, including ALN-HTT02, have moved into the clinical development stage. There has been increased research focus on the development of gene silencing approaches, viral vectors, and precision medicine in recent years, hence improving the landscape. Owing to numerous ongoing clinical development projects focused on gene therapy, RNA interference, and other advanced technologies, the market for Huntington’s disease treatments is shifting from managing the symptoms to treating the root cause of the disease.
The Huntington's disease market is limited owing to the scarcity of the condition and difficulties in designing clinical trials involving a rare and scattered patient population. It is necessary to involve patients from different countries to find enough participants, which increases development times and costs of research and development. Moreover, great genetic diversity and the presence of a significant number of CAG repeat length differences lead to the presence of different disease development patterns, different onsets of symptoms, and different outcomes. Those patients who have large expansions tend to have early-onset and rapid disease progression, whereas other patients have different disease development patterns, which increases the complexity of clinical testing. Moreover, the extremely low frequency of rare disease subgroups, such as homozygous Huntington's disease, further limits opportunities of conducting clinical trials.
A major opportunity exists in the development of preventive treatments for presymptomatic people harboring the mutation leading to Huntington's disease. With developments in the fields of neuroimaging techniques, fluid biomarkers, and genetic testing, it is now possible to identify individuals who will eventually develop the disease years before they develop symptoms, thus generating a completely new segment that can be targeted for prevention through therapeutics.
Disease-modifying gene therapy, RNA therapy, neuroprotective drugs, and cognitive interventions are among the strategies that can be used in slowing down the onset of symptoms. The use of biomarkers as primary endpoints in clinical trials has increased recently, which will help to expedite regulatory evaluation and facilitate treatment of presymptomatic individuals. As precision medicine evolves, development of preventive treatment will gain a lot of importance in industry. Development of successful preventive treatments will create enormous commercial opportunity in the world market for Huntington's disease therapeutics.
The increasing use of biomarkers in the form of blood tests for disease monitoring has been noted to be one of the major trends in the market for Huntington's disease. The use of biomarkers, which include neurofilament light chain (NfL), phosphorylated tau, and mutant huntingtin protein, has been increasing due to their use in monitoring the progress of the disease, treatment response, and even identifying the disease among individuals before symptoms become apparent. Their increased adoption in the field of clinical trials has been facilitating the faster evaluation of disease-modifying therapies. The use of blood tests allows for easy monitoring without the need for invasive methods like collecting cerebrospinal fluid or undergoing imaging tests.
North America takes the lead position in the global Huntington’s disease market by generating maximum revenue because of the highly developed healthcare system, the presence of specialty centers for movement disorders, and a well-developed rare disease research environment in the region. The United States is the leader within the region based on a large pool of diagnosed patients, genetic testing, patient registries, and involvement in clinical trials worldwide. Favorable reimbursement policies, pharmaceutical investments, and regulatory frameworks fast-track the uptake of novel treatment solutions, including novel RNA and gene therapies.
Disease awareness, well-developed patient registries, and legislation related to healthcare of rare diseases in Europe contribute to it being the second largest market for Huntington’s disease. The UK, Germany, and France lead the way due to their advanced diagnostic capabilities, neurology centers, and participation in international clinical trials. As a result of centralization of the healthcare system and laws concerning the approval of orphan drugs, patients can get modern treatment and reimbursement. For successful market growth throughout the forecast period, there must be efficient collaboration of research organizations, hospitals, and patient groups.
The reasons behind the fast-growing market in Asia Pacific include the development of healthcare infrastructure, availability of genetic testing, and information about rare diseases. The leading country in terms of market development in the region is China because of its advanced healthcare, neurological facilities, and participation in clinical trials on a global scale. Japan provides a substantial contribution due to its developed research infrastructure, advanced diagnostics, and elderly population, enabling the detection and treatment of the disease. India is becoming a potentially growing market owing to the development of neurological services, health insurance, and involvement in global research projects. Market growth is expected during the whole forecast period due to investments in precision medicine, rare diseases, and innovative drugs.
The symptomatic treatment currently holds the lion's share of the Huntington's disease market, where treatments approved help control cholera, psychiatric issues, and motor impairment, with no impact on the disease process. The most popular drugs used include vesicular monoamine transport inhibitors, antipsychotics, antidepressants, and complementary drugs for improving the quality of life. Nevertheless, the disease-modifying treatments are the fastest-growing segments due to innovations related to gene therapy, RNA-based therapy, and neuroprotective drugs developed to target the root cause of the disease.
The antipsychotics segment constitutes the largest drug class in the HD market owing to its capacity to treat cholera along with the associated psychiatric disorders. The monoamine depletors are also significant players in the market and have been serving as the only treatments approved so far for treating motor impairments. Depressants and anti-anxiety drugs are essential for treating the coexisting conditions of depression and anxiety, among others. It is predicted that the development of newer and more tolerable psychiatric drugs would help in promoting future growth in the market.
Chorea management is one of the most significant indication segments, which will have a market value of USD 385 million in 2025 and 60% of the total pharmaceutical spending for symptomatic treatment, owing to the indications approved by the FDA for the use of monoamine depleters and the existing treatment guidelines. Psychiatric symptom management has a market value of USD 165 million and 26% of total pharmaceutical spending for the treatment of psychiatric symptoms like depression, anxiety, and behavioral problems in most HD patients.
Hospital networks and neurology clinics comprise 56% of the market size, with a value of USD 362 million in 2025, owing to the high concentration of complicated treatment of Huntington's disease in specialized healthcare facilities. Such specialized centers offer a multidisciplinary approach in managing the disease with the integration of neurology, psychiatry, neuropsychology, and physiotherapy treatments. The movement disorder specialists occupy 28% of the total market size.
The treatment market for Huntington’s disease worldwide is moderately concentrated, with the top seven companies accounting for about 58-65% of market value through their symptomatic treatment products, disease-modifying therapy product development pipelines, and academic research collaborations. Competitive strengths lie in disease-modifying therapeutic approaches; superior clinical development programs proving efficacy in many dimensions of the disease; healthcare professional networks; and patient support group collaboration to recruit patients for trials and create awareness of treatment options.
February 2025: Latus Bio developed new computational models to predict the impact of MSH3 gene knockdown in terms of CAG repeat expansion, implying the possibility of a one-shot disease-modifying therapeutic approach that can target fundamental problems in Huntington's disease pathogenesis by MSH3.
December 2024: uniQure was granted FDA clearance to file a Biologics License Application for their AMT-130 gene therapy using an accelerated approval route with a unified Huntington's Disease Rating Scale being used as a main efficacy outcome and reduced cerebrospinal fluid neurofilament light chain as supporting data.
April 2025: Pritenia Therapeutics formed collaboration and licensing agreements with Ferrer to market pridopidine in Europe and selected countries, with the European Medicines Agency Committee for Medicinal Products for Human Use assessment scheduled for mid-2025.
December 2024: UCLH conducted the first human clinical trial for ALN-HTT02 RNA interference treatment developed by Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, which is the first-in-human study of RNA interference for huntingtin protein.
October 2024: H. Lundbeck A/S acquired Longboard Pharmaceuticals for USD 2.6 billion to improve its capability in developing new neurological drug candidates.
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
24 Aug 2026
Intellectual Market Insights Research © 2026. All rights reserved.
